Mesalazine Has No Effect on Mucosal Immune Biomarkers in Patients with Diarrhea-Dominant Irritable Bowel Syndrome Referred to Shariati Hospital: A Randomized Double-Blind, Placebo-Controlled Trial

BACKGROUND Intestinal mast cells may cause gastrointestinal symptoms in patients with diarrhea-dominant irritable bowel syndrome (IBS). The objective of this study was to determine the effect of mesalazine on the number of lamina propria mast cells and clinical manifestations of patients with diarrh...

Descripción completa

Detalles Bibliográficos
Autores principales: Ghadir, Mohammad Reza, Poradineh, Mehri, Sotodeh, Masoud, Ansari, Reza, Kolahdoozan, Shadi, Hormati, Ahmad, Yousefi, Mohammad Hosein, Mirzaei, Samaneh, Vahedi, Homayoon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Iranian Association of Gastroerterology and Hepatology 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5308130/
https://www.ncbi.nlm.nih.gov/pubmed/28316762
http://dx.doi.org/10.15171/mejdd.2016.47

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5308130/
https://www.ncbi.nlm.nih.gov/pubmed/28316762
http://dx.doi.org/10.15171/mejdd.2016.47

Ejemplares similares